Abstract
BackgroundHumanistic burden considers the impact of an illness on a patient’s health-related quality of life (HRQoL), activities of daily living (ADL), caregiver health, and caregiver QoL. Humanistic burden also considers treatment satisfaction and adherence to treatment regimens. Pompe disease is an autosomal recessive, progressive, multisystemic neuromuscular disease. Approval of enzyme-replacement therapy (ERT) markedly improved prognosis for patients, but considerable morbidity and a substantial humanistic burden remain. This article characterizes the humanistic burden of Pompe disease through a systematic literature review.MethodsA systematic search of MEDLINE® and Embase® with back-referencing and supplementary literature searches was performed to retrieve data from interventional and non-interventional studies on the humanistic burden of Pompe disease. Publications were screened according to predefined criteria, extracted, and assessed for quality. Extracted data were narratively synthesized.ResultsNo publications on the humanistic burden of infantile-onset Pompe disease (IOPD) were identified. As such, of 17 publications included here, all are in patients with late-onset Pompe disease (LOPD). Thirteen publications were initiated after approval of ERT, two were initiated before, and two overlapped the approval of ERT. The review shows that LOPD patients have a significantly lower HRQoL than the general population, even if treated with ERT. On transitioning to ERT, treatment was associated with improvement in the physical component score of the SF-36 and fatigue, although the SF-36 mental component score remained stable. Physical HRQoL remained below population norms after 4 years of ERT. Significantly more ERT-treated patients reported pain than controls, and bodily pain worsened in later years following ERT initiation. Treatment-naïve LOPD patients had significantly poorer ADL functioning compared with the general population, although ERT stabilized deteriorating functioning impairment. ERT studies showed caregivers provide 17.7 h/week informal care on average. Fifty percent, 40% and <20% of caregivers reported mental health, physical health, and financial/relational problems, respectively. In ERT-naïve patients, wheelchair use and home ventilatory support was associated with lower physical HRQoL and ADL functioning. In ERT-treated patients, key factors predicting worse HRQoL and ADL functioning were higher respiratory distress, poorer sleep quality, greater pain, and more fatigue.ConclusionsPompe disease has a substantial humanistic burden, with strong inter-relationships among and between humanistic burden parameters and clinical progression.
Highlights
Humanistic burden considers the impact of an illness on a patient’s health-related quality of life (HRQoL), activities of daily living (ADL), caregiver health, and caregiver QoL
What is the impact of Pompe disease on humanistic burden in patients receiving enzyme-replacement therapy (ERT) throughout the course of clinical studies, and in patients transitioning from supportive treatment to ERT during the course of a clinical study? What inter-relationships exist among humanistic burden parameters in Pompe disease? How does the humanistic burden change as the disease progresses? What is the impact of ERT on the humanistic burden of Pompe disease?
This systematic review demonstrates that late-onset Pompe disease (LOPD) has a substantial humanistic burden that is clearly associated with clinical disease progression; patients with more severe disease have increased fatigue, more pain, poorer QoL, and less ability to perform ADL
Summary
Humanistic burden considers the impact of an illness on a patient’s health-related quality of life (HRQoL), activities of daily living (ADL), caregiver health, and caregiver QoL. Humanistic burden considers treatment satisfaction and adherence to treatment regimens. The humanistic burden takes into account patients’ treatment satisfaction and adherence to their specific treatment regimen. Pompe disease is an autosomal recessive, progressive, debilitating disease in which acid α-glucosidase (GAA) deficiency leads to intralysosomal accumulations of glycogen in all tissues. Infants with IOPD typically present during the first few weeks of life with hypotonia, progressive weakness, macroglossia, hepatomegaly, and hypertrophic cardiomyopathy. This presentation usually facilitates identification of the disorder [7, 8]; identifying LOPD can be more challenging as these patients generally present with slowly progressive limb girdle-type weakness and ventilatory insufficiency without significant cardiomyopathy. The laboratory diagnosis of Pompe disease depends on the measurement of GAA activity in the blood or tissues, or the detection of disease-causing variants in the GAA gene
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.